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over $2 in 1995 to just under $18 in 2005 (year 2005
Canadian dollars). Over the same period, the difference
in inflation-adjusted per capita expenditures on
prescription drugs between the 2 countries grew from
approximately $31 to approximately $356 (year 2005
Canadian dollars).
Some have suggested that the recent growth in
pharmaceutical expenditures in the United States has
been driven in part by the fact that the proportion of
pharmaceutical purchases paid for out of pocket is
falling.
12 However, out-of-pocket spending has
represented a steadily declining share of US
expenditures on prescription drugs since 1960, with the
most rapid decline occurring between 1989 and 1996,
before the major changes illustrated in Figure 2(data
provided in the appendices).
That the difference in prescription drug
expenditures per capita between Canada and the
United States would start to rise in the mid-1990s in
apparent lockstep with the new phenomenon of
spending on DTCA in the United States, after 20 years
of relative stasis, would be a rather remarkable
coincidence. There have been no other policy,
demographic or economic changes that could explain
the direction, magnitude and timing of the recent
divergence between the 2 countries' per capita
expenditures on prescription drugs.
The recent divergence in per capita expenditures
between Canada and the United States gives an
indication of the potential impact of increased DTCA in
Canada and possibly of the introduction of DTCA in
countries where it is currently not permitted. If, over
the last decade, Canada had followed a path of DTCA
similar to that taken by the United States and if per
capita expenditures on prescription drugs had risen as
much in Canada as they have in the United States,
Canadian expenditures on prescription drugs would be
approximately $10 billion higher per year than they
currently are. This amount would be sufficient to pay
annual salaries of $250,000 to 40,000 physicians.
The DTCA-associated increased spending on
prescription drugs may be of value if it is on treatments
that are appropriate and cost-effective. However, after
reviewing studies published to 2004, Gilbody and
colleagues concluded that, while DTCA is associated
with increased requests for and use of advertised
products, no health benefits have been established.
13 A
more recent study involving standardized patients
randomly assigned to make no request, brand-specific
requests or general requests for treatment of
adjustment disorder or major depression found that
general and brand-specific requests resulted in better
quality of care (defined as receiving some form of
treatment for their condition).
14 Not surprisingly,
patients who request a specific brand are more likely to
receive that specific brand rather than available
alternatives.
14
It is certainly desirable to make better use of
prescription drugs in Canada, although doing so may
result in increased pharmaceutical expenditures.
However, to promote safe, effective and efficient
medicine use, policy-makers would be well advised to
maintain and enhance restrictions on product-claim
(brand-specific) DTCA, because such advertisements
are designed to instill product preferences in people
who often do not have the information, training or
incentive to compare the risks, benefits and costs of the
available treatment options.
If, owing to a lack of economic incentive for
nonbranded advertising, manufacturers fail to promote
awareness of conditions that are critical to the health of
the population, the appropriate public policy response
would be to invest in publicly sponsored campaigns to
promote better use of prescription drugs, not to relax
restrictions on product-claim DTCA and thereby give
manufacturers the opportunity to instil brand
preferences in patients. The potential impact of
product-claim DTCA on the Canadian health system is
simply too large to accept such advertising before other
ways of better use of prescription drugs have been
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